Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Mineralys Therapeutics Inc.
MLYS | US
30.07
USD-0.51
-1.67%
MLYS | US
About Mineralys Therapeutics Inc.
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
20/04/2026
Close
30.07
Open
30.37
High
30.37
Low
29.52
Mineralys Therapeutics Inc. a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat a proprietary orally administered highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor Pennsylvania.
View LessMLYS | US
Risk
79.1
Sharpe
1.13
Luna's Score
51/100
Recommendation
Hold
Luna says (MLYS | US)
What's Working
Value Stock (Price to Book < 3)
What's not Working
Smallcap (300M - 2B USD)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
63.1%1 month
79.1%3 months
65.2%6 months
61.8%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.47
Debt to equity
-
Debt to assets
-
Ent. to EBITDA
-7.41
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-
MarketCap
1.50B
MarketCap(USD)
1.50B
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-41.62
Short ratio
14.21
Short perc.
4.67
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
5.40
Range1M
9.06
Range3M
12.23
Volumes: Market Activity
Rel. volume
0.46
Price X volume
16.90M
